ReviewEndocrinology and metabolism clinics of North America2015
Pituitary tumors.
Review in Endocrinology and metabolism clinics of North America, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 1 synthesis or guideline pooled it, 81 citations in OpenAlex.
- Systematic review and network meta-analysis assess the comparative efficacy and safety of transsphenoidal surgery for pituitary tumor.Neurosurgical review · 2021Pooled it
- Clinician decision-making in non-functioning pituitary adenomas: an Australian and New Zealand interdisciplinary survey study.Pituitary · 2026Article
- DRD2 Deficiency Underlies Pituitary Adenoma Dependent on Escherichia coli Translocation from the Gut.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Application and Outcomes of Indocyanine Green in Endoscopic Transsphenoidal Surgery for Functional Pituitary Tumors: A Literature Review.Brain sciences · 2026Review
- Causal relationship between gut microbiota and pituitary neuroendocrine tumors: a bidirectional Mendelian randomization.Discover oncology · 2025Article
- Rethinking MRI Protocols for Pituitary Microadenomas: Prioritizing Non-Contrast Imaging for Safe Follow-Up.Tomography (Ann Arbor, Mich.) · 2025Article
- Pituitary Macroadenoma: A Comprehensive Case Study of Surgical Intervention and Postoperative Management.Cureus · 2024Article
- Advancements in pseudouridine modifying enzyme and cancer.Frontiers in cell and developmental biology · 2024Review
- Article
- Differential expression levels of β-catenin are associated with invasive behavior of both functional and non-functional pituitary neuroendocrine tumor (PitNET).Molecular biology reports · 2023Article
- MicroRNA-137 inhibits pituitary prolactinoma proliferation by targeting AKT2.Journal of endocrinological investigation · 2023Article
- Recent Therapeutic Advances in Pituitary Carcinoma.Journal of immunotherapy and precision oncology · 2023Review
- Molecular characterization of epithelial-mesenchymal transition and medical treatment related-genes in non-functioning pituitary neuroendocrine tumors.Frontiers in endocrinology · 2023Article
- The microenvironment of pituitary adenomas: biological, clinical and therapeutical implications.Pituitary · 2022Review
- Cost-Utility of Acromegaly Pharmacological Treatments in a French Context.Frontiers in endocrinology · 2021Article
- Article
- Cyclin A in nonfunctioning pituitary adenomas.Endocrine · 2020Article
- Article
- Transnasal Transsphenoidal Approach for Pituitary Tumors: An ENT Perspective.Indian journal of otolaryngology and head and neck surgery : official publication of the Association of Otolaryngologists of India · 2020Article
- Involvement of GPR4 in increased growth hormone and prolactin expressions by extracellular acidification in MtT/S cells.The Journal of reproduction and development · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
Pituitary tumors are commonly encountered intracranial neoplasms that are invariably benign. Classic oncogene mutations are not encountered in these tumors, and disrupted cell cycle control and growth factor signaling likely contribute to pathogenesis and natural history. They have unique clinical features that are determined by the secreted hormone gene product.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.